TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27885751
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with Defibrillation (CRT-D) in prolonged baseline PR interval subgroup
Study: 22190528
Drug: Compound anisodine
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound anisodine injection (CA group)
Study: 22190528
Drug: Venoruton tablets
DrugBank: Oxerutins (DB15826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton tablets (control group)
Study: 19644045
Drug: Budesonide/formoterol (320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (320/9 microg) plus tiotropium (18 microg once daily)
Study: 11430175
Drug: SSRIs (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (selective serotonin reuptake inhibitors) as first-line treatment for depressive and anxiety disorders
Study: 11430175
Drug: Newer antidepressants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antidepressants (venlafaxine, bupropion, nefazodone, mirtazapine)
Study: 7932276
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (2,500 lux) between 0600 and 0800 hours
Study: 7932276
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (2,500 lux)
Study: 15784928
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac (30 mg)
Study: 7491331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no theophylline treatment)
Study: 22723577
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure therapy
Study: 27282690
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment using a short leg cast or splint (Group A)
Study: 14624026
Drug: Daily dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosage of vitamin C
Study: 14624026
Drug: Daily dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosage of vitamin E
Study: 10900277
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg orally twice daily) and 0.45 percent saline intravenously
Study: 8922661
Drug: HRT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT treatment groups
Study: 30847930
Drug: Oestrogen administration
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen administration (EE)
Study: 30847930
Drug: Endothelin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin B receptor (ETB R) inhibition (BQ-788)
Study: 30847930
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution alone
Study: 30021634
Drug: Orlistat treatment
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat treatment for 1-3 months before IVF-ET
Study: 30021634
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 1-3 months before IVF-ET
Study: 18775878
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (discharged 24h after first PM implant or 4-6h after replacement, followed with Home-Monitoring for 4 weeks)
Study: 10656234
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of thioctic acid (TA) t.i.d. for 3 weeks
Study: 1523284
Drug: Chlorpromazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (12.5 mg orally)
Study: 1523284
Drug: Chlorpromazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25 mg orally)
Study: 1523284
Drug: Lorazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.5 mg orally)
Study: 4043516
Drug: Furosemide-triamterene combination
Normalized name: furosemide / triamterene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide-triamterene combination
Study: 31142081
Drug: Sublingual 5
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual 5 mg nifedipine dripping pills
Study: 31142081
Drug: Sublingual 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 10 mg nifedipine dripping pills
Study: 29034961
Drug: Automated intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated intermittent boluses with 16 mg ropivacaine every 2 hours combined with patient-controlled administration
Study: 29034961
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 8 mg/h (4 ml/h) of ropivacaine combined with patient-controlled administration (2 ml, lockout time 30 min)
Study: 27061887
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose subcutaneous zoster vaccine
Study: 27061887
Drug: 1/3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3 dose subcutaneous zoster vaccine
Study: 27061887
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose intradermal zoster vaccine
Study: 27061887
Drug: 1/3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3 dose intradermal zoster vaccine
Study: 27061887
Drug: 1/10 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 dose intradermal zoster vaccine
Study: 27061887
Drug: 1/27 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/27 dose intradermal zoster vaccine
Study: 27061887
Drug: All intradermal
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intradermal doses
Study: 24659236
Drug: rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide (100 mg tid) + LDA (100 mg once-daily)
Study: 24659236
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + LDA + clopidogrel (75 mg once-daily)
Study: 16415603
Drug: Propranolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 1.0 mg
Study: 16415603
Drug: Propranolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.5 mg
Study: 12570169
Drug: Bromocriptine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (7.5 mg continuously) combined with clomiphene citrate (150 mg from day 5 to 9)
Study: 12570169
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with clomiphene citrate (150 mg from day 5 to 9)
Study: 12570169
Drug: Bromocriptine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine and placebo treatment
Study: 9456562
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: 38 children (76 eyes) with birth weight from 580 to 1500 g (mean 1158 g)
Study: 9456562
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 52 children (104 eyes) with birth weight from 1501 to 2450 g (mean 2093 g)
Study: 2844546
Drug: RX77368 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RX77368 infusion
Study: 2844546
Drug: Domperidone during
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone during RX77368 infusion
Study: 31276454
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose 1 (0.06%)
Study: 31276454
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose 2 (0.08%)
Study: 27007062
Drug: N-acetylcysteine (1200-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200-3000 mg/d)
Study: 11669432
Drug: Remifentanil anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil anaesthesia (boluses and infusion)
Study: 30362981
Drug: Capacitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive and resistive electric transfer (CRET) therapy
Study: 22773282
Drug: Carotenoid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin)
Study: 18165564
Drug: Propofol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (6 mg x kg(‐1) x h(‐1) for 10 min followed by 2.4 mg x kg(‐1) x h(‐1))
Study: 3537245
Drug: Furosemide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (single dose)
Study: 3537245
Drug: Furosemide (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (long-term therapy)
Study: 29905619
Drug: MMF capsule
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF capsule
Study: 29905619
Drug: MMF dispersible
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF dispersible tablet
Study: 27637335
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) - 0.092 g EPA+DHA/kg body weight/day
Study: 18551124
Drug: Insulin users
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin users (88 participants, 54% of total)
Study: 18551124
Drug: Insulin users
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin users (after adjustment)
Study: 10353514
Drug: RRV‐TV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐TV vaccine
Study: 8626881
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg immediate-release (IR) verapamil every 8 hours
Study: 8626881
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg controlled-release (CR) formulation once daily
Study: 8626881
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (IR and CR)
Study: 2123907
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy (Group C)
Study: 2123907
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (conventional therapy)
Study: 6994665
Drug: Metrifonate at
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate at 10 mg/kg body weight for three days
Study: 6994665
Drug: Metrifonate at
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate at 10 mg/kg body weight for six days
Study: 28948706
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after successful reperfusion for AMI added on top of optimal standard of care.
Study: 23453612
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin antibiotic prophylaxis
Study: 19781270
Drug: Two-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose steroid combined with two-dose daclizumab and tacrolimus
Study: 19781270
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol (steroid withdrawn after 3 months)
Study: 9140670
Drug: Nisoldipine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (0.05 mg intracoronary during procedure, followed by 20 mg/day orally for 6 months)
Study: 9140670
Drug: Nitrates (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (0.8 mg intracoronary during procedure, followed by 80-120 mg/day orally for 6 months)
Study: 7526025
Drug: Physiologic concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic concentrations of the platelet specific agonist ADP
Study: 2889217
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexchlorpheniramine maleate 3-times daily
Study: 4686554
Drug: Inhaled aerosols
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosols of prostaglandin F(2)alpha (PGF(2)alpha)
Study: 4686554
Drug: Inhaled aerosols
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosols of histamine
Study: 4686554
Drug: Inhaled aerosols
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosols of prostaglandin E(2) (PGE(2))
Study: 4686554
Drug: Simultaneous inhalation
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous inhalation of a 100-times higher PGE(2) dose with PGF(2)alpha
Study: 23559676
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (without GH)
Study: 16914701
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin)
Study: 14992900
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion)
Study: 14992900
Drug: Heparin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (150 to 300 U/kg bolus) with protamine reversal
Study: 8489977
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine alone (Control)
Study: 26133666
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ER niacin)
Study: 23205593
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Behavioural Therapy (SCBT)
Study: 23205593
Drug: Enhanced Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive Behaviour Therapy (ECBT)
Study: 15972298
Drug: Azathioprine 2
Normalized name: azathioprine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2 mg/kg/day
Study: 15972298
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid 3.2 g/day
Study: 12947422
Drug: Ordinary caviar
Normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary caviar paste (25 g daily for 3 weeks)
Study: 12947422
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil enriched caviar paste (25 g daily for 3 weeks)
Study: 11930370
Drug: Resin-bonded bridges
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin-bonded bridges with grooves in abutment teeth preparation
Study: 6130952
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg etintidine
Study: 6130952
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg etintidine
Study: 27487406
Drug: Oscillatory Biofield
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillatory Biofield Therapy (OBFT)
Study: 24717640
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg, orally once a day for 6 months)
Study: 22908774
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg administered without cost for 4 months (Group A)
Study: 22908774
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg administered with cost for 4 months (Group B)
Study: 22908774
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg administered without cost (Group A)
Study: 22908774
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg administered with cost (Group B)
Study: 18333867
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral (14)C‐labelled maraviroc
Study: 18333867
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous maraviroc
Study: 18333867
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral maraviroc
Study: 15819354
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel containing ACP
Study: 12464983
Drug: Quinapril (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (titrated up to 40 mg daily)
Study: 2475322
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 mg/kg)
Study: 319408
Drug: Beclamid (3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclamid (3-6 tablets a day according to weight)
Study: 23939537
Drug: Zolpidem sublingual
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem sublingual tablet (ZST) 3.5 mg in fed state
Study: 23939537
Drug: Zolpidem sublingual
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem sublingual tablet (ZST) 3.5 mg in fasting state
Study: 23939537
Drug: Zolpidem sublingual
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem sublingual tablet (ZST) in fed state
Study: 23939537
Drug: Zolpidem sublingual
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem sublingual tablet (ZST) in fasting state
Study: 21878080
Drug: Fenofibrate (Tricor)
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate (Tricor) administered early (first 7 days) after myocardial revascularization
Study: 2371597
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (5-FU) continuous regimen (5% cream applied nightly for 6 weeks)
Study: 2371597
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (5-FU) periodic regimen (5% cream applied 2 consecutive nights per week for 10 weeks)
Study: 345887
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release ephedrine-theophylline-phenobarbital (ETP) tablet
Study: 345887
Drug: Terbutaline tablets
Normalized name: terbutaline Oral Tablet
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline tablets
Study: 28841649
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination)
Study: 28841649
Drug: Infliximab added
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab added on to the FIN-RACo DMARD combination
Study: 28841649
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added on to the FIN-RACo DMARD combination
Study: 12515749
Drug: Control (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dietary therapy alone)
Study: 9890856
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy for 2 months
Study: 2296877
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of oral anticoagulants (Group A)
Study: 2296877
Drug: Aspirin, 650
Normalized name: Aspirin, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 650 mg/day (Group B)
Study: 2296877
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy (Group C)
Study: 6971092
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg intravenous every 4 hours for 48 hours, followed by 1 g oral daily for 10 days)
Study: 30847561
Drug: Inositol 2
Normalized name: inositol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 2 g plus 200 µg of folic acid (twice daily for 3 months)
Study: 30847561
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily plus 200 µg of folic acid
Study: 30847561
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg per day for 5 days (with folic acid)
Study: 30847561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 µg of folic acid as placebo)
Study: 23338657
Drug: Propiverine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine extended-release (ER) 45 mg s.i.d.
Study: 23338657
Drug: Propiverine immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine immediate-release (IR) 15 mg t.i.d.
Study: 19728607
Drug: Standard AO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AO plate via L-shaped incision
Study: 17503974
Drug: Aripiprazole 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10, 15, 20, or 30 mg/day
Study: 7524460
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) KIU in the pump prime solution)
Study: 3066983
Drug: Bemithyl (actoprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemithyl (actoprotective agent)
Study: 24094768
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg intravenously once every 2 weeks
Study: 22937831
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 250 mg once a day
Study: 17409822
Drug: Gemcitabine (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1100 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 8) every 28 days
Study: 17409822
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 1) every 21 days
Study: 8736419
Drug: Orofacial physiotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial physiotherapeutic treatment (OPT)